Process for the preparation of antibody-drug conjugates
Patent Information
- Application Number
- EP2023703091
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-17
- Filing Date
- 2023-01-16
- Publication Date
- 2024-11-27
AI Technical Summary
Current methods for preparing antibody-drug conjugates face challenges in controlling the number of drug molecules conjugated to antibodies, leading to variability in therapeutic efficacy and stability.
A process is developed to prepare a mixture of antibody-drug conjugates with controlled attachment of 2, 3, or 5 molecules of interest to the antibody, using specific attachment heads and click chemistry, resulting in conjugates with structures A, B, or C, which are characterized by high resolution mass spectrometry.
The process ensures a consistent drug-antibody ratio, enhancing therapeutic efficacy and stability by achieving a predominantly homogeneous population of antibody-drug conjugates with 2, 3, or 5 molecules attached, suitable for cancer treatment.
Smart Images

Figure IMGF000004_0001 
Figure IMGF000005_0001 
Figure IMGF000006_0001
Abstract
Description
[0001] Process for the preparation of antibody-drug conjugates
[0002] Technical Field
[0003] The present invention relates to a process for preparing a mixture of antibody-drug conjugates (in English "Antibody Drug Conjugate" or "ADC") and the conjugates capable of being obtained by this process.
[0004] State of the art
[0005] The early 2000s saw an intensification of research on antibody-drug conjugates (ADCs), these conjugates potentially representing an alternative or a complement to "conventional" therapies for the targeted delivery of an active ingredient, particularly a cytotoxic drug. The antibody-drug conjugate therefore makes it possible to combine the specificity of targeting by antibodies with new powerful effector functions by the agents conjugated to them.
[0006] The structure of an antibody-drug conjugate typically consists of an antibody linked to the drug by a molecule, one part of which will bind the antibody and another part of which will couple to the drug, generally via a spacer arm (or linker) of variable length and nature.
[0007] After binding to its target antigen, the antibody is most often internalized into the cell by receptor-mediated endocytosis. The vesicles fuse with lysosomes where the drug is released from the antibody via various mechanisms. The active drug then acts directly on the cell, inducing its death, and sometimes on neighboring cancer cells through transport or diffusion into the environment. The antibody is therefore primarily used as a vector, delivering the drug to the target cell.
[0008] Antibody-drug conjugates are described in application WO 2015 / 004400. Furthermore, application WO 2022 / 018371 describes attachment heads which make it possible to obtain compounds which, when conjugated to proteins, in particular antibodies, make it possible to obtain a “structure” such that on average the number of attachment heads conjugated per protein (antibody) is controlled: the majority conjugate targeted carrying either 1 molecule per protein (antibody) or 2 molecules per protein (antibody), the term “molecule” designating in this document either a compound of formula (I), or a compound of formula (II) or the click reaction product between a compound of formula (I) and a compound of formula (V). Summary of the invention
[0009] The present invention relates to a process for preparing a mixture of conjugates comprising predominantly either a conjugate of structure (A), or a conjugate of structure (B), or a conjugate of structure (C), these conjugates being as defined below.
[0010] The present invention also relates to a mixture of conjugates obtainable by the above-mentioned method.
[0011] The present invention also relates to a composition containing such a mixture of conjugates, and the use of this composition as a medicament, in particular for the treatment of cancer.
[0012] Definitions
[0013] The term "antibody" refers to a heterotetramer consisting of two heavy chains of approximately 50-70 kDa each (called the H chains for Heavy) and two light chains of approximately 25 kDa each (called the L chains for Light), linked together by interchain disulfide bridges. Each chain consists, in the N-terminal position, of a variable region or domain, called VL for the light chain, VH for the heavy chain, and in the C-terminal position, of a constant region, consisting of a single domain called CL for the light chain and three or four domains called CHI, CH2, CH3, CH4, for the heavy chain.
[0014] The term "F(ab')2" refers to an antibody fragment that retains the ability of the antibody to bind to an antigen. The F(ab')2 fragment is obtained by enzymatic digestion of immunoglobulins with pepsin or IdeS. F(ab')2 is formed from two Fab' fragments linked by interchain disulfide bridges. The Fab' fragment consists of the Fab region (consisting of the variable regions and the CH1 and CL domains) and a hinge region.
[0015] In the context of the present disclosure, the term "antibody" means both a heterotetramer as defined above and an F(ab')2 fragment of said heterotetramer. Thus, when referring to the reaction of an antibody with a compound of formula (X), this reaction includes the reaction of the F(ab')2 fragment of the antibody with said compound of formula (X).
[0016] The term "mixture of conjugates comprising predominantly a conjugate of structure (A)" means the product resulting from the implementation of the process in accordance with the invention, comprising more than 50% by mass of conjugate of structure (A), the remainder of the mixture being constituted by-product(s) of the reaction (leading predominantly to the production of said conjugate of structure (A)). Such a mixture does not comprise either the conjugate of structure (B) or the conjugate of structure (C). The same definition applies by analogy to the expressions "mixture of conjugates comprising predominantly a conjugate of structure (B)" and "mixture of conjugates comprising predominantly a conjugate of structure (C)".
[0017] Brief description of the figures
[0018] Figures 1A, 1B and 1C respectively represent the structure of the conjugates of structure (A), (B) and (C) obtained by the process according to the invention. In these figures, the black circle represents a hook head, the gray square represents a linking arm, the gray oval represents a spacer, and the ovoid shape containing the letter M represents an active ingredient.
[0019] For the reasons indicated above, the structures shown in these figures include both a whole antibody and an F(ab')2 fragment of that antibody.
[0020] Detailed description of the invention
[0021] According to a first aspect, the invention relates to a method for preparing a mixture of antibody-drug conjugates comprising predominantly either a conjugate of structure (A) as represented in Figure 1A, or a conjugate of structure (B) as represented in Figure 1B, or a conjugate of structure (C) as represented in Figure 1C; structures in which: the symbol • represents a hook head of formula (IIa), (IIb), (IIe) or (IId): in which:
[0022] - T represents -(CH2) y - , y being an integer ranging from 0 to 6;
[0023] - W is -ORa, -COR2, -CONR3R4OR -NR3COR4;
[0024] - R a is -(CH2CH2O) q -(CH2) r -R5, -(CR c R d ) r -R5, <OR b , -(CR c R d ) r -NHCO-(CH2CH2O) q -(CH2) r -R5, -(CR c R d ) r -CONH-(CH2CH2O)q -(CH2) r -R5, -(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R5 or -(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R5;
[0025] R b ester -(CH2CH2O) q -(CH2) r -R5, -O(CH2CH2O) q -(CH2) r -R5, -(CR c R d ) r -R5,
[0026] -O(CR c R d ) r -R5, -(CR c R d ) r -NHCO-(CH2CH2O) q -(CH2) r -R5, -(CR c R d ) r -CONH-(CH2CH2O) q -(CH2) r - R5, -(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R5 OU -(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R5;
[0027] - R2est -(CH2CH2O) q -(CH2) r -R5, -(CR c R d )r -Rs, -O(CH2CH2O) q -(CH2) r -R5, -O(CR c R d ) r -R5,
[0028] -O(CR c R d ) r -NHCO-(CH2CH2O) q -(CH2) r -R5, -O(CR c R d ) r -CONH-(CH2CH2O) q -(CH2) r -R5,
[0029] -O(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R5ou -O(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R5;
[0030] - R3 is -H, -(C1-C6)alkyl or -(CH2) V -SO3H, preferably R3est -H or -(C1-C6)alkyl;
[0031] R4est -(CH2CH2O) q R5, -(CR c R d ) r R5, -(CR c R d ) r -NHCO-(CH2CH2O) q -R5, -(CR c R d ) r -CONH-(CH2CH2O) q -R5, -(CH2CH2O) q -(CH2) r -NHCO-(CRc R d ) r -R5, -(CH2CH2O) q - (CH2) r -CONH-(CR c R d ) r -R5, -CH-[(CR c R d ) r -CONH-(CR c R d ) r -(OCH2CH2) q -R5]2, -CH-[(CR c R d ) r - NHCO-(CR c R d ) r -(OCH2CH2) q -R5]2, -CH-[(CR c R d ) r -CONH-(CR c R d ) r -R5]2, ou -CH-[(CR c R d ) r - NHCO-(CR c R d ) r -R5]2, de préférence R4est -(CH2CH2O) q R5, -(CR c R d ) r R5, -(CR c R d ) r -NHCO-(CH2CH2O) q -R5, -(CR c R d ) r -CONH-(CH2CH2O) q -R5, -(CH2CH2O) q - (CH2) r -NHCO-(CR c R d ) r -R5, ou -(CH2CH2O) q -(CH2)r -CONH-(CR c R d ) r -R5;
[0032] - each R5 is -(CH2) s R6;
[0033] - each R6 is chosen from:
[0034]
[0035]
[0036] - R c is H ;
[0037] - each R d is selected from -H, -CH2-SO3H or -SO3H;
[0038] - R7 is -H or -CH3; - each q is an integer ranging from 1 to 24;
[0039] - each r is an integer ranging from 1 to 8;
[0040] - each s is an integer ranging from 0 to 6;
[0041] - each v is an integer from 1 to 6; the symbol represents a link arm which is a direct link; a bridge -SS-; or a group of formula -R 11 -(HAS) Z - ;
[0042] - Ru is a direct bond, a group R6-(CR c R d ) r -CO-, R6-(CH2CH2O) q-(CH2) s -CO-, R6-(CR c R d X-NH-, where R6, R c , R d , q, r and s are as defined above;
[0043] - A is an amino acid residue;
[0044] - z is equal to 1, 2, 3, 4 or 5; the symbol represents a spacer which is a direct bond or a group of formula:
[0045] - G is a sulfate, a sugar, a glucuronide, or a galactoside, said sugar being a saccharide group preferably selected from a beta-glucuronic acid, a beta-D-galactose, a beta-D-glucose, an alpha-D-mannose, an N-acetyl-D-glucosaminyl, an N-acetyl-D-galactosaminyl, a D-glucuronyl, an L-iduronyl, a D-glucopyranosyl, a D-galactopyranosyl, a D-mannopyranosyl or an L-fucopyranosyl, preferably G is a sulfate, a beta-glucuronic acid, or a beta-D-galactose;
[0046] - Ri2 is -H or -NO2;
[0047] M is a molecule of interest; it being understood that: each conjugate comprises at least one attachment head of formula (Ha) or (Ilb), in each of the aforementioned conjugates, at least one of the linker arm and the spacer is present; said preparation method comprising: al) the reaction of an antibody with a compound of formula (II'a) or (ITb): bl) the reaction of the compound obtained in step al) with a compound of formula (II'a) or with a compound of formula (II'b), or with a compound of formula (II'c) or with a compound of formula (II'd): in which T and W are as defined above; it being understood that:
[0048] - if a compound (II'a) is used in step a1) and a compound (II'a) is used in step b1), the two compounds (II'a) have a different structure;
[0049] - if a compound (ITb) is used in step a1) and a compound (ITb) is used in step b1), the two compounds (Il'b) have a different structure; cl) the reaction of the compound obtained in step b1) with two identical or different compounds, each corresponding to formula (III): in which:
[0050] - R8est R6-(CR c R d ) r -CO-, R6-(CH2CH2O) q -(CH2) s -CO-, R6-(CR c R d ) r -NH-, where R6, R c , R d , q, r and s are as defined above;
[0051] - the connecting arm, the spacer and M are as defined above- above, M being identical or not in each compound (III); or else al) the reaction of an antibody with a compound of formula (II'a) or (II'b); b2) the reaction of the compound obtained in step al) with a compound of formula (IV): in which: i) the attachment head is a compound of formula (II"a), (II"b), (II"c), or (II"d):
[0052] in which:
[0053] - T is as defined above;
[0054] - Y is -OR'a, -COR'2, -CONR'3R'4 or -NR'3COR'4
[0055] - R' a is -(CH2CH2O) q -(CH2) r -R'5, -(CR c R d X-R'5, -COR' b , -(CR c R d ) r -NHCO-(CH2CH2O) q -(CH2) r - R'5, -(CR c R d ) r -CONH-(CH2CH2O) q -(CH2) r -R'5, -(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R'5 or -(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R'5 ;
[0056] R' b is -(CH2CH2O) q -(CH2) r -R'5, -O(CH2CH2O) q -(CH2) r -R'5, -(CR c Rd kR'5,
[0057] -O(CR c R d ) r -R'5, -(CR c R d ) r -NHCO-(CH2CH2O) q -(CH2) r -R'5, -(CR c R d ) r -CONH-(CH2CH2O) q -(CH2) r - R'5, -(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R'5 OU -(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R'5;
[0058] - R'2est -OH, -(CH2CH2O) q -(CH2) r -R'5, -(CR c R d X-R'5, -O(CH2CH2O) q -(CH2) r -R'5, -O(CR c R d ) r - R'5, -O(CR c R d ) r -NHCO-(CH2CH2O) q -(CH2) r -R'5, -O(CR c R d ) r -CONH-(CH2CH2O) q -(CH2) r -R'5, -O(CH2CH2O) q -(CH2) r -NHCO-(CR c R d )r -R'5 ou -O(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R'5 ;
[0059] - R3est -H, -(C1-C6)alkyle ou -(CH2) V -SO3H, de préférence R'3est -H ou -(C1-C6)alkyle ;
[0060] R4est -(CH2CH2O) q R'5, -(CR c R r )R'5, -(CR c R d ) r -NHCO-(CH2CH2O) q -R'5, -(CR c R d ) r -CONH-(CH2CH2O) q -R'5, -(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R'5, -(CH2CH2O) q - (CH2) r -CONH-(CR c R d ) r -R'5, -CH-[(CR c R d ) r -CONH-(CR c R d ) r -(OCH2CH2) q -R'5]2, -CH-[(CR c R d ) r - NHCO-(CR c R d ) r -(OCH2CH2) q -R'5]2, -CH-[(CR c R d )r -CONH-(CR c R d ) r -R'5]2, ou -CH-[(CR c R d ),- NHCO-(CR c R d ) r -R'5]2, de préférence R'4est -(CH2CH2O) q R'5, -(CR c R d ) r R'5, -(CR c R d ) r -NHCO-(CH2CH2O) q -R'5, -(CR c R d ) r -CONH-(CH2CH2O) q -R'5, -(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R'5, OU -(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R'5;
[0061] - chaque R'5est -(CH2) S R'6ou -(CH2) S R'7;
[0062] - R'6est choisi parmi :
[0063]
[0064] - R'7est -COOH ou -NR'8R'9;
[0065] - R'8est -H, -(C1-C6)alkyle ; - R'9est -H, -(C1-C6)alkyle ;
[0066] - R' 10is -H or -CH3; where R c , R d , q, r and s are as defined above; and ii) the linker arm is a direct bond; a bridge -SS-; or a group of formula - R'ii-(A) Z - ; - R' 11 - is a direct bond, a group R'6-(CR c R d ) r -CO-, R'6-(CH2CH2O) q -(CH2) s -CO-, R'6-
[0067] (CR c R d ) r -NH-, where R'6, RC, R d , q, r and s are as defined above;
[0068] - A is an amino acid residue;
[0069] - z is equal to 1, 2, 3, 4 or 5; and iii) the spacer and M are as defined in step c1), it being understood that the linker arm and the spacer cannot simultaneously be a direct bond; c2) the reaction of the compound obtained in step b2) with a compound of formula (III) as defined in step c1), the molecule of interest M of compound (III) being identical to or different from the molecule of interest M of compound (IV); or al) the reaction of an antibody with a compound of formula (II'a) or (IIb); b3) the reaction of the compound obtained in step a1) with a compound of formula (III) as defined above; c3) the reaction of the compound obtained in step b3) with a compound of formula (IV) as defined above, the molecule of interest M of compound (IV) being identical to or different from the molecule of interest M of compound (III); or al) the reaction of an antibody with a compound of formula (II'a) or (ITb);b3) the reaction of the compound obtained in step a1) with a compound of formula (III) as defined above; c4) the reaction of the compound obtained in step b3) with a compound of formula (II'a), (IIb), (II'c) or (IId) as defined above; dl) the reaction of the compound obtained in step c4) with a compound of formula (III) as defined above, the molecule of interest M being identical or not in each compound (III).;
[0070] The antibody-drug conjugates of formula (I) may also be prepared by a process comprising: a2) reacting an antibody with a compound of formula (IV) as defined above, wherein the attachment head is solely a compound of formula (II"a) or (II"b); b4) reacting the compound obtained in step a2) with a compound of formula (IV) as defined above, M being identical or not in each compound (IV), it being understood that:
[0071] - if a compound (II"a) is used in step a2) and a compound (II"a) is used in step b4), the two compounds (II"a) have a different structure;
[0072] - if a compound (II"b) is used in step a2) and a compound (II"b) is used in step b4), the two compounds (II"b) have a different structure; or a2) the reaction of an antibody with a compound of formula (IV) as defined above, in which the attachment head is only a compound of formula (II"a) or (II"b); b5) the reaction of the compound obtained in step a2) with a compound of formula (II'a), (II'b), (II'c) or (II'd) as defined above; c5) the reaction of the compound obtained in step b5) with a compound of formula (III) as defined above, the molecule of interest M of the compound (III) being identical to or different from the molecule of interest M of the compound (IV).
[0073] Step a1) of the method of the invention consists in reacting an antibody (a term which includes, as indicated above, the F(ab')2 fragment of said antibody) with a binding head of formula (II'a) or (II'b). The antibody binds to the binding head by a substitution reaction of the Br groups present in formula (II'a) or (II'b).
[0074] In some embodiments, the antibody is reacted with the attachment head in the presence of a reducing agent. In some embodiments, the attachment head and the reducing agent are present in excess, relative to the antibody. By "excess" is meant (and this is applicable for the description and the claims) an amount (expressed as an equivalent) at least 2 times greater, for example at least 5 times, at least 10 times or at least 15 times greater. In some embodiments, the attachment head is in solution in a water-miscible solvent or a mixture of water-miscible solvents.
[0075] At the end of step a1), we obtain a “compound” with a structure as shown in figure 2.
[0076] Step b1) of the process of the invention consists in reacting the compound obtained in step a1) with a second attachment head, distinct from that used in step a1), of formula (II'a), (II'b), (II'c) or (II'd). In a similar manner to that indicated for step a1), the antibody binds to the second attachment head by a substitution reaction of the Br groups present in the formula (II'a), (II'b), (II'c) or (II'd).
[0077] In some embodiments, the compound obtained in step a1) is reacted with the second attachment head in the presence of a reducing agent. In some embodiments, an excess of second attachment head and reducing agent is used, relative to the compound obtained in step a1). In some embodiments, the compound obtained in step a1) is first reacted with the reducing agent, and then the second attachment head is added. In some embodiments, the second attachment head is dissolved in a water-miscible solvent or a mixture of water-miscible solvents.
[0078] At the end of step b1) a “compound” with a structure as shown in Figure 3 is obtained. Step c1) of the process of the invention consists of reacting the compound obtained at the end of step b1) with two identical or different compounds of formula (III).
[0079] In some embodiments, an excess of each of the compounds of formula (III) is used, relative to the compound obtained in step b1). In some embodiments, the compounds of formula (III) are each in solution in a water-miscible solvent or a mixture of water-miscible solvents. In some embodiments, the two compounds of formula (III) are added concomitantly. In some embodiments, the two compounds of formula (III) are added sequentially.
[0080] The reaction between the compound obtained in step b1) and the two compounds of formula (III) is carried out by “click” chemistry. This reaction takes place between a group R6 carried by each of the attachment heads and a group R6 carried by each of the compounds of formula (III). More precisely, the click reaction takes place between a diene (for example an azide or a diazo) and a dienophile (for example an alkene or an alkyne), each of these functions being provided by a group R6. Thus, the click reaction can take place between a diene provided by the group R6 of each of the attachment heads and a dienophile provided by the group R6 of the compound (III), or between a dienophile provided by the group R6 of each of the attachment heads and a diene provided by the group R6 of the compound (III). These click reactions are well known to those skilled in the art, it being understood that the groups R6 are judiciously chosen to be compatible with each other.When the two compounds of formula (III) are added concomitantly, the click reaction is carried out in a single step. When the two compounds of formula (III) are added sequentially, two successive click reactions are carried out, the order of addition of the compounds of formula (III) being a function of the compatibility of the click functions (R6) used.
[0081] In certain embodiments, the compound obtained in step a1) and / or the compound obtained in step b1) may be purified before being used in the following step. In the same way, when the click reaction is carried out in a single step, the mixture of conjugates obtained at the end of step c1) may also be purified. When two successive click reactions are carried out in step c1), purification may take place at the end of one or the other click reaction (or both). The purification is carried out according to techniques well known to those skilled in the art. At the end of step c1), a mixture of conjugates is obtained, the majority conjugate of which is as shown in Figure 1A, 1B, or 1C. This majority conjugate has 2, 3 or 5 molecules of interest M carried by the antibody.
[0082] Step b2) of the process of the invention consists of reacting the compound obtained in step a1) with a compound of formula (IV).
[0083] In some embodiments, the compound obtained in step a1) is reacted with the compound of formula (IV) in the presence of a reducing agent. In some embodiments, an excess of compound of formula (IV) and reducing agent is used, relative to the compound obtained in step a1). In some embodiments, the compound of formula (IV) is in solution in a water-miscible solvent or a mixture of water-miscible solvents.
[0084] At the end of step b2) we obtain a “compound” having one of the structures as shown in figure 4.
[0085] Step c2) of the process of the invention consists of reacting the compound obtained in step b2) with a compound of formula (III). This step is carried out by click reaction according to a method similar to that described for step c1).
[0086] In some embodiments, an excess of compound of formula (III) is used, relative to the compound obtained in step b2). In some embodiments, the compound of formula (III) is in solution in a water-miscible solvent or a mixture of water-miscible solvents.
[0087] In certain embodiments, the compound obtained in step a1) and / or the compound obtained in step b2) may be purified before being used in the following step. In the same way, the mixture of conjugates obtained at the end of step c2) may also be purified. The purification is carried out according to techniques well known to those skilled in the art.
[0088] At the end of step c2), a mixture of conjugates is obtained, the majority conjugate of which is as shown in Figure 1A, 1B or 1C. This majority conjugate has 2, 3 or 5 molecules of interest M carried by the antibody.
[0089] Step b3) of the process of the invention consists of reacting the compound obtained in step a1) with a compound of formula (III).
[0090] This step is carried out by click reaction using a method similar to that described for step cl).
[0091] In some embodiments, an excess of compound of formula (III) is used, relative to the compound obtained in step a1). In some embodiments, the compound of formula (III) is in solution in a water-miscible solvent or a mixture of water-miscible solvents.
[0092] At the end of step b3) we obtain a “compound” with a structure as shown in figure 5.
[0093] Step c3) of the process of the invention consists of reacting the compound obtained in step b3) with a compound of formula (IV).
[0094] In some embodiments, the compound obtained in step b3) is reacted with the compound of formula (IV) in the presence of a reducing agent. In some embodiments, an excess of compound of formula (IV) and reducing agent is used, relative to the compound obtained in step b3). In some embodiments, the compound of formula (IV) is in solution in a water-miscible solvent or a mixture of water-miscible solvents.
[0095] In certain embodiments, the compound obtained in step a1) and / or the compound obtained in step b3) may be purified before being used in the following step. In the same way, the mixture of conjugates obtained at the end of step c3) may also be purified. The purification is carried out according to techniques well known to those skilled in the art.
[0096] At the end of step c3), a mixture of conjugates is obtained, the majority conjugate of which is as shown in Figure 1A, 1B or 1C. This majority conjugate has 2, 3 or 5 molecules of interest M carried by the antibody.
[0097] Step c4) of the process of the invention consists of reacting the compound obtained in step b3) with a second attachment head, of formula (II'a), (ITb), (II'c) or (ITd).
[0098] In some embodiments, the compound obtained in step b3) is reacted with the second attachment head in the presence of a reducing agent. In some embodiments, an excess of second attachment head and reducing agent is used, relative to the compound obtained in step b3). In some embodiments, the compound obtained in step b3) is first reacted with the reducing agent, and then the second attachment head is added. In some embodiments, the second attachment head is dissolved in a water-miscible solvent or a mixture of water-miscible solvents.
[0099] At the end of step c4) we obtain a “compound” having one of the structures as shown in figure 6.
[0100] Step dl) of the process of the invention consists of reacting the compound obtained in step c4) with a compound of formula (III). This step is carried out by click reaction according to a method similar to that described for step cl).
[0101] In some embodiments, an excess of compound of formula (III) is used, relative to the compound obtained in step c4). In some embodiments, the compound of formula (III) is in solution in a water-miscible solvent or a mixture of water-miscible solvents.
[0102] In certain embodiments, the compound obtained in step a1) and / or the compound obtained in step b3) and / or the compound obtained in step c4) may be purified before being used in the following step. In the same way, the mixture of conjugates obtained at the end of step dl) may also be purified. The purification is carried out according to techniques well known to those skilled in the art.
[0103] At the end of step dl), a mixture of conjugates is obtained, the majority conjugate of which is as shown in Figure 1A, 1B or 1C. This majority conjugate has 2, 3 or 5 molecules of interest M carried by the antibody.
[0104] Step a2) of the method of the invention consists in reacting an antibody with a compound of formula (IV) as defined above, in which the attachment head corresponds only to formula (II"a) or (II"b). The antibody binds to the attachment head of compound (IV) by a substitution reaction of the Br groups present in formula (II"a) or (II"b).
[0105] In some embodiments, the antibody is reacted with the compound of formula (IV) in the presence of a reducing agent. In some embodiments, an excess of compound of formula (IV) and reducing agent is used, relative to the antibody. In some embodiments, the compound of formula (IV) is in solution in a water-miscible solvent or a mixture of water-miscible solvents.
[0106] At the end of step a2) we obtain a “compound” with a structure as shown in figure 7.
[0107] Step b4) consists of reacting the compound obtained in step a2) with a second compound of formula (IV).
[0108] In some embodiments, the compound obtained in step a2) is reacted with the second compound of formula (IV) in the presence of a reducing agent. In some embodiments, an excess of the second compound of formula (IV) and reducing agent is used, relative to the compound obtained in step a2). In some embodiments, the second compound of formula (IV) is in solution in a water-miscible solvent or a mixture of water-miscible solvents. In some embodiments, the compound obtained in step a2) may be purified before being used in the next step. In the same way, the mixture of conjugates obtained at the end of step b4) may also be purified. The purification is carried out according to techniques well known to those skilled in the art.
[0109] At the end of step b4), a mixture of conjugates is obtained, the majority conjugate of which is as shown in Figure 1A, 1B or 1C. This majority conjugate has 2, 3 or 5 molecules of interest M carried by the antibody.
[0110] Step b5) of the process of the invention consists of reacting the compound obtained in step a2) with a binding head of formula (II'a), (ITb), (II'c) or (ITd).
[0111] In some embodiments, the compound obtained in step a2) is reacted with the anchor head in the presence of a reducing agent. In some embodiments, an excess of anchor head and reducing agent is used, relative to the compound obtained in step a2). In some embodiments, the compound obtained in step a2) is first reacted with the reducing agent, and then the anchor head is added. In some embodiments, the anchor head is dissolved in a water-miscible solvent or a mixture of water-miscible solvents.
[0112] At the end of step b5) we obtain a “compound” having one of the structures as shown in figure 8.
[0113] Step c5) of the process of the invention consists of reacting the compound obtained in step b5) with a compound of formula (III).
[0114] This step is carried out by click reaction using a method similar to that described for step cl).
[0115] In some embodiments, an excess of compound of formula (III) is used, relative to the compound obtained in step b5). In some embodiments, the compound of formula (III) is in solution in a water-miscible solvent or a mixture of water-miscible solvents.
[0116] In certain embodiments, the compound obtained in step a2) and / or the compound obtained in step b5) may be purified before being used in the following step. In the same way, the mixture of conjugates obtained at the end of step c5) may also be purified. The purification is carried out according to techniques well known to those skilled in the art.
[0117] At the end of step c5), a mixture of conjugates is obtained, the majority conjugate of which is as shown in Figure 1A, 1B or 1C. This majority conjugate has 2, 3 or 5 molecules of interest M carried by the antibody. Some of the embodiments described above involve a reducing agent. The person skilled in the art will know how to judiciously choose such an agent from the compounds conventionally used in bioconjugation reactions; for example, the following may be mentioned: dithiothreitol, beta-mercaptoethanol, tris(2-carboxyethyl)phosphine hydrochloride or tris(hydroxypropyl)phosphine.
[0118] In certain embodiments, the method according to the invention comprises steps a1), b1) and c1).
[0119] In certain embodiments, the attachment head used in step a1) corresponds to one of the formulas (II'a) or (II'b), and the attachment head used in step b1) corresponds to one of the formulas (II'a), (II'b), (II'c) or (II'd), in which:
[0120] - W is -CONR3R4 or -NR3COR4, preferably W is -CONR3R4;
[0121] - R3 is -H or -(C1-C6)alkyl;
[0122] - R4is -(CH2CH2O)q-(CH2) r _ R5, or -(CR c j) r - 5
[0123] - R6 is chosen from:
[0124] - R c , R d are as defined above;
[0125] - q is an integer ranging from 1 to 12, preferably q is an integer ranging from 1 to 8;
[0126] - r is an integer ranging from 1 to 6. In certain embodiments, the attachment head is a compound of formula (II'al),
[0127] (II'a2), (II'a3), (II'a4), (II'a5), or (II'a6):
[0128]
[0129] In certain embodiments, the method according to the invention comprises steps a1), b2) and c2). In certain embodiments, the attachment head used in step b2) corresponds to one of the formulas (II"a), (II"b), (II"c) or (II"d) in which:
[0130] - Y is -CONR'3R'4OR -NR'3COR'4, preferably Y is -CONR'3R'4;
[0131] - R'3 is -H or -(C1-C6)alkyl;
[0132] - R'4is -(CH2CH2O)q _ (CH2) r -R'5, or -(CR c R d ) r -R'5 ; - R'5 is -(CH2) S R'6;
[0133] - R'6 is chosen from:
[0134]
[0135] - R c , R d are as defined above;
[0136] - q is an integer ranging from 1 to 12, preferably q is an integer ranging from 1 to 8;
[0137] - r is an integer ranging from 1 to 6. In certain embodiments, the attachment head is a compound of formula (II"a1), (II"a2), (II"a3), (II"a4), (II"a5), (II"a6), (II"a7), (II"a8) or (II"bl):
[0138]
[0139] In some embodiments, the link arm is a direct link (in which case the spacer is not a direct link).
[0140] In some embodiments, the linker arm is a group of formula -Rn-(A) Z - in which Ru and A are as defined above, and z is equal to 2, 3 or 4.
[0141] A is an amino acid residue which may be selected from the group consisting of: valine, citrulline, phenylalanine, lysine, aspartic acid, methionine, asparagine, proline, isoleucine, alanine, arginine, glycine or glutamic acid. Advantageously, z is equal to 2 or 3, preferably 2 and -(A) z - is an amino acid residue selected from the residue of: valine-citrulline; phenylalanine-lysine; valine-alanine; valine-aspartic acid; lysine-methionine; lysine-asparagine; proline-isoleucine; proline-lysine; valine-lysine; alanine-lysine; phenylalanine-phenylalanine-lysine; phenylalanine-phenylalanine-alanine; arginine-arginine; lysine-arginine; lysine-glutamic acid; glycine-arginine; or glycine-glycine-arginine (the order of the amino acids is given here for information, for example a citrulline-valine residue is also included in the definition of -(A) z -).
[0142] In some embodiments, the spacer is a direct bond (in which case the linker arm is not a direct bond) or a group of the formula: preferably a direct bond or a group of formula:
[0143] In certain embodiments, M is an active ingredient. As an active ingredient that may be used in the context of the invention, mention may be made of the active ingredients of drugs already authorized and molecules currently undergoing therapeutic evaluation, in particular:
[0144] - alkylating agents such as: chlorambucil, chlornaphazine, cyclophosphamide, dacarbazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, mannomustine, mitobronitol, melphalan, mitolactol, pipobroman, novembichine, phenesterin, prednimustine, thiotepa, trofosfamide, uracil mustard, CC-1065 (including its synthetic analogues adozelesin, carzelesin and bizeleesin), duocarmycin (including the synthetic analogues KW-2189 and CBI-TMI), benzodiazepine dimers (e.g., pyrrolobenzodiazepine (PBD) dimers or tomaymycin, indolinobenzodiazepines, imidazobenzothiadiazepines, or oxazolidino-benzodiazepines), nitroureas (carmustine, lomustine, chlorozotocin, fotemustine, nimustine, ranimustine), alkylsulfonates (busulfan, treosulfan, improsulfan and piposulfan), triazenes (dacarbazine), platinum-based compounds (carboplatin, cisplatin, oxaliplatin), aziridines (benzodopa, carboquone, meturedopa, and uredopa),ethyleneimines and melamines (including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine);,
[0145] - plant alkaloids such as: Vinca alkaloids (vincristine, vinblastine, vindesine, vinorelbine, navelbine), taxoids (paclitaxel, docetaxol) and their analogues, maytansinoids (DM1, DM2, DM3, DM4, maytansine and ansamitocins) and their analogues, cryptophycins (in particular cryptophycin 1 and cryptophycin 8), epothilones, eleutherobine, discodermolide, bryostatins, dolastatins, auristatins, tubulysins, cephalostatins, pancratistatins, sarcodictyin, spongistatins;
[0146] - DNA topoisomerase inhibitors such as: epipodophyllin (9-aminocamptothecin, camptothecin, crisnatol, daunomycin, etoposide, etoposide phosphate, irinotecan, mitoxantrone, novantrone, retinoic acids (retinols), teniposide, topotecan, 9-nitrocamptothecin (RFS 2000), mitomycins (mitomycin C), bortezomib;
[0147] - anti-metabolites such as: anti-folates (DHFR inhibitors (methotrexate, trimetrexate, denopterin, pteropterin, aminopterin (4-aminopteroic acid) and other folic acid analogues), IMP dehydrogenase inhibitors (mycophenolic acid, tiazofurin, ribavirin, EICAR), ribonucleotide reductase inhibitors (hydroxyurea, deferoxamine), pyrimidine analogues such as: uracil analogues (ancitabine, azacitidine, 6-azauridine, capecitabine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, 5-fluorouracil, floxuridine, ratitexed), cytosine analogues (cytarabine, cytosine arabinoside, fludarabine), purine analogues (azathioprine, fludarabine, mercaptopurine, thiamiprine, thioguanine), folinic acid;
[0148] - hormonal agents such as: antiestrogens (megestrol, raloxifene, tamoxifen), LHRH agonists (goserelin, leuprolide acetate), antiandrogens (bicalutamide, flutamide, calusterone, dromostanolone propionate, epitiostanol, goserelin, leuprolide, mepitiostane, nilutamide, testolactone, trilostane), vitamin D3 analogues (CB 1093, EB 1089, KH 1060, cholecalciferol, ergocalciferol), photodynamic therapies (verteporfin, phthalocyanine, photosensitizer Pc4), cytokines (interferon-alpha, interferon-gamma, tumor necrosis factor (TNF), human TNF domain-containing proteins); - kinase inhibitors such as: BIBW 2992, CYT387, E7080, axitinib, bafetinib, bosutinib, cabozantinib, dasatinib, erlotinib, gefitinib, imatinib, iniparib, ispinesib, lapatinib, masitinib, mubritinib, nilotinib, pazopanib, pegaptanib, ponatinib, ruxolitinib, sorafenib, sunitinib, tivozanib, vandetanib, vismodegib;
[0149] - poly(ADP-ribose)polymerase (PARP) inhibitors such as: BGB-290, CEP 9722,
[0150] E7016, 3-aminobenzamide, niraparib, olaparib, talazoparib, veliparib;
[0151] - immunomodulators such as: thalidomide, lenalidomide, pomalidomide;
[0152] - a toxin such as pseudomonas exotoxin (PE), Bouganin, Bouganin;
[0153] - anthracycline and derivatives of this active ingredient;
[0154] - oligonucleotides.
[0155] In a particular embodiment, the active ingredient is selected from methotrexate, an immunomodulator, duocarmycin, combretastatin, calicheamicin, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), maytansine, DM1, DM4, SN38, amanitin and its analogues, pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, pyrrolopyridodiazepine, a pyrrolopyridodiazepine dimer, a histone deacetylase inhibitor, a tyrosine kinase inhibitor, and ricin, preferably the active ingredient is amanitin, a pyrrolobenzodiazepine dimer, MMAF or MMAE, the latter two being represented by the following formulas:
[0156] In some embodiments, M is a radionuclide chelator. Examples of radionuclide chelators that may be used in the context of the invention include sarcophagine, DOTA (1,4,7,10-tetraazacyclododecane-A( / V, / V', / V"-tetraacetic acid), DOTAGA (tetraazacyclododecane triacetic acid glutaric acid), NODA (1,4,7-triazacyclononane-1,4-diacetic acid), NODAGA (triazacyclononane diacetic acid glutaric acid), NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and MANOTA (methyl amino triazacyclononane triacetic acid).
[0157] In some embodiments, the antibody or FCatQz fragment of said antibody binds to a cancer-specific antigen. The cancer-specific antigen may be, for example, CD1a, CD3, CD4, CD13, CD19, CD20, CD21, CD22, CD25, CD30, CD33, CD34, CD37, CD39, CD40, CD44, CD47, CD52, CD56, CD66e, CD70, CD72, CD73, CD74, CD79, CD80, CD86, CD117, CD138, CD194, CD205, CD227, VEGF, EpCAM, GPIIb, GPIIIa, TNF alpha, TNFR, TNT, Lewis Y, EGFR, HER-2, HER-3, HER-4, AXL, Protein F, IgE-Fc, C5, IL-6R, IL12, IL15, IL18, IL23, IL-1, TPO-R, GPNMB, PSMA, PSA, PAP, PSM, Cripto, Folate receptor 1, endothelin receptors ETB, STEAP1, SLC44A4 (AGS-5), AGS-16, Guanylyl cyclase C, EGFRvIII, Mesothelin, IL2R, A33, Can, VEGFR-1, VEGFR-2, VEGFR-3, TGFbeta, TGFbetaR, FGF, FGFR, PDGF, PDGFR, Ang-1, Ang-2, integrin, RANK-L, BLyS, c-MET, DR, TCRalpha,beta, ICOS, EphA2, CA6, ENPP3, FOLR1, Nectin-4, TIM-1, tissue factor, LIV-1, TLR-7, AFP, HLA-DR, carcinoembryonic antigen (CEA),TAG-72, folate binding protein, G250, gangliosides, collagen type 4 (collagen IV), collagen type 18 (collagen XVIII), CA19-9, pl85HER2, fibroblast activation protein (FAP), tenascin, metalloproteinases, endosialin, carbonic anhydrase, Galectin 9, Aldolase A, eIFgamma4, Galectin 4, HERKV-K10, p53, NY-LU-12, Restin, NY-CO-38, SSX2, NY-ESO-1, SCP-1, HGFR, PTK 7, CCK-4, PTP-LAR, CDCP1, CADM1, IGSF4, BCAM, CEACAM6, JAM-A, PTGFRN (CD9P-1), MCAM, MCP, EMMPRIN, TfR, ClqR, hTERT, Survivin, MDM2, CYP1B1, MART-1, MART-2, melanosomal proteins, gplOO, CDC27, MAGEs, WT1, MUM-1, MUM-2, MUM-3, BRAF, TPI, fibronectin, K-ras, beta-catenin, CDK4, caspase-8, pl4ARF, pl6INK4a, bcr-abl, SYT-SSX, TRP-1, TRP-2, GnT-V, tyrosinase, TEL-AML1, proteinase 3, EBV-EBNA, HTLV-1 tax, HPV16-E7, mutated HLA-A2, HAÏ, SART3, CEACAM5, ESAT-6, RANK, fibrin, TF, PRAME, CA19-9, CA50, CA195, CAM17.1 / WGA, beta-MG, DU-PAN2, HE4, transferrin, transthyretin, ApoAl, TROP-2, CTLA-4, GITR,PD- 1, PD-L1, c-KIT, CD11b-CD18 integrin heterodimer, DNA / Histone H1, proteoglycan, fibrinogen, SV40 large T antigen, SC-Ag, ESA, mucin, CCR4, MTX1, MTX2, PECAM, Tn, cathepsin D, TYRO-3, MER, or a PF4 / heparin complex. In some embodiments, the antibody binds to HER2, CD30, or CD56. For example, the antibody may be an anti-HER2 antibody, an anti-CD30 antibody, or an anti-CD56 antibody.
[0158] The antibody may be of mammalian (e.g., human or mouse), murine, chimeric, humanized, or human origin. It is preferably a monoclonal antibody produced recombinantly by genetically modified cells using techniques widely described in the literature.
[0159] In some embodiments, the antibody is of the IgG type, for example IgG1, IgG2,
[0160] IgG3 or IgG4.
[0161] Compounds of formula (III): can be obtained in a conventional manner, for example by peptide-type coupling between on the one hand the linker arm (carrying the Rs group) and the spacer, and on the other hand between the spacer and M. Such coupling is carried out in a conventional manner between a carboxylic group carried by the linker arm (respectively, the spacer), and an amine group carried by the spacer (respectively M).
[0162] Compounds of formula (IV): can be purchased or obtained for example as described in application WO 2022 / 018371 or in application WO 2020 / 234541. In particular, when the attachment head of formula (II"a), (II"b), (II"c) or (II"d) comprises a substituent Y = COR'2 with R'2 = OH, its coupling with the linker arm can occur when the latter is a group of formula -R'n-(A) Z - (and R' 11- = direct bond), via a peptide bond between the carboxylic group from Y and an amino group from A (amino acid residue). When the linker arm is absent and the anchor head of formula (II"a), (II"b), (II"c) or (II"d) comprises a substituent Y = COR'2 with R'2 = OH, the coupling of the anchor head with the spacer occurs, always via a peptide bond, between the carboxylic group from Y and an amino group from the spacer.
[0163] Similarly, the coupling between the anchor head and the linker arm (or, if applicable, the spacer) can occur via a peptide bond when R'5 is -(CH2) S R'7 with R'7= -COOH, as explained above. The coupling between the anchor head and the spacer, when R'5 is -(CH2) S R'7 with R'7= -NR'5R9g can intervene via a peptide bond between the amino group from R'7 and a carboxylic group from the spacer.
[0164] The preparation method of the invention makes it possible to obtain a mixture of antibody-drug conjugates comprising predominantly (i.e. > 50% by mass) either a conjugate of structure (A), or a conjugate of structure (B), or a conjugate of structure (C). This mixture of conjugates is therefore characterized in that it predominantly contains either a conjugate which comprises 2 molecules of interest M fixed on the antibody, or a conjugate which comprises 3 molecules of interest M fixed on the antibody, or a conjugate which comprises 5 molecules of interest M fixed on the antibody. The molecules of interest M fixed on each antibody may be identical or different. A mixture comprising mainly a conjugate of structure (A) does not comprise either a conjugate of structure (B) or a conjugate of structure (C), but comprises in a minor way (< 50% by mass) one or more by-products of the reaction which led to the production of the conjugate of structure (A).A mixture comprising mainly a conjugate of structure (B) does not comprise either a conjugate of structure (A) or a conjugate of structure (C), but comprises in a minor way (< 50% by mass) one or more by-products of the reaction which led to the production of the conjugate of structure (B). A mixture comprising mainly a conjugate of structure (C) does not comprise either a conjugate of structure (A) or a conjugate of structure (B), but comprises in a minor way (< 50% by mass) one or more by-products of the reaction which led to the production of the conjugate of structure (C). The proportion of the expected species (2, 3 or 5 molecules of interest M) is determined by HRMS (High Resolution Mass Spectrometry) analysis under denaturing conditions. When the conjugates of structure (A), (B) or (C) comprise a whole antibody, the analysis is carried out either on the compound as such, or after digestion of the conjugates by IdeS, on the FCab^ fragment.The mixture of conjugates obtained by the process of the invention may be present in a composition, which may be for example a pharmaceutical composition containing one or more pharmaceutically acceptable excipients and / or vehicles.
[0165] Thus, according to another aspect, the invention relates to a composition comprising a mixture of antibody-drug conjugates, as defined above, capable of being obtained by the method described above. As indicated above, this mixture mainly contains an antibody-drug conjugate which comprises 2, 3 or 5 molecules of interest M attached to the antibody.
[0166] In certain embodiments, when the mixture predominantly contains a conjugate of structure (A), the 2 M molecules attached to the antibody are different from each other.
[0167] According to another aspect, the invention relates to a composition as defined above for use as a medicament.
[0168] The invention is illustrated by the following examples, given purely for illustrative purposes. In these examples, the following abbreviations are used:
[0169] DAR = drug-antibody ratio
[0170] DCC = dicyclohexylcarbodiimide
[0171] DIPEA = A( / V-diisopropylethylamine
[0172] DMAP = 4-dimethylaminopyridine
[0173] DMF = A( / V-dimethylformamide
[0174] DM SO = dimethyl sulfoxide
[0175] EDTA = ethylenediaminetetraacetic acid
[0176] ESI: Ionization by electrospray
[0177] HCl = hydrochloric acid
[0178] HOBt = hydroxybenzotriazole
[0179] MeCN = acetonitrile
[0180] MeOH = methanol
[0181] MMAE = monomethyl auristatin E
[0182] MMAF = monomethyl auristatin F
[0183] NaCI = sodium chloride
[0184] NMR: Nuclear Magnetic Resonance
[0185] HRMS: High-resolution mass spectrometry
[0186] TA = room temperature (20°C unless otherwise stated)
[0187] TFA = trifluoroacetic acid tR = retention time
[0188] UV = ultraviolet v / v = volume to volume ratio
[0189] Analysis methods
[0190] Nuclear magnetic resonance (NMR) spectroscopy Proton nuclear magnetic resonance (NMR) spectra 1 H were performed on a Bruker Ultrashield 300 instrument (300 MHz ^H). Analyses were performed in deuterated methanol (CD3OD). Chemical shifts (5) are measured in parts per million (ppm) relative to the residual signal of deuterated methanol (^H = 3.31 ppm).
[0191] The coupling constants ( ) are expressed in Hertz (Hz) and the multiplicity is described as follows: m = multiplet, s = singlet, t = triplet.
[0192] High-resolution mass spectrometry (HRMS)
[0193] The exact mass of the synthesized compounds was determined by high-resolution mass spectrometry (HRMS) in positive or negative mode with the electrospray ionization technique ESI, on a Bruker maXis mass spectrometer coupled to a Dionex Ultimate 3000 RSLC system of the “Research Federation” platform of the ICOA / CBM (FR2708).
[0194] Denaturing high-resolution mass spectrometry (HRMS)
[0195] To eliminate sugar-related heterogeneity and increase the mass response, in some cases, the Fc parts of the antibodies to be analyzed were cleaved using IdeS protease. Conjugate analysis was therefore performed on a sample previously cleaved by IdeS protease: 1 pL of IdeS at a concentration of 0.8 g / L was added to 10 pL of sample and the sample was then incubated at 37 °C for at least 16 h. Spectrometric analysis of the conjugates was performed on a Bruker maXis mass spectrometer coupled to a Dionex Ultimate 3000 RSLC system. Prior to MS analysis, samples (5 pg) were desalted on a MassPREP desalting column (2.1x10 mm, Waters), heated to 80 °C using 0.1% aqueous formic acid as solvent A and 0.1% formic acid in acetonitrile as solvent B at 500 pL / min. After 1 min, a linear gradient from 5 to 90% B in 1.5 min was applied.MS data were acquired in positive mode with an ESI source over a m / z range of 900 to 5000 at 1 Hz and analyzed using DataAnalysis 4.4 software (Bruker) and the MaxEnt algorithm for deconvolution. The proportion of species of interest obtained was determined using the intensity of the species peaks observed on the F(ab')2 fragment.
[0196] Bioconjugation reactions
[0197] Preparation of solutions
[0198] Buffer 1: 1 X phosphate buffer (1 mM KH2PO4, 180 mM NaCI and 3 mM
[0199] Na2HPO4.7H2O) at a pH of 8.3 and a final EDTA concentration of 1 mM.
[0200] Buffer 2: 1 X phosphate buffer (1 mM KH2PO4, 180 mM NaCI and 3 mM
[0201] Na2HPO4.7H2O) at pH 7.4. Reducing agent: Tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) solution at a concentration of 1 mM in buffer 1.
[0202] Bioconversion reaction 1
[0203] The antibody solution in buffer 1 (1.0 eq) was placed under argon. The solution of the compound of formula (II'a), (IIb), (II'a) or (IIb) (1.0-15.0 eq, preferably 3.0-12.0 eq) then the reducing agent solution (1.0-12.0 eq, preferably 3.0-8.0 eq) were added and the reaction medium was stirred under argon at 25 °C or 37 °C for 2 h 30 min.
[0204] Purification 1
[0205] If necessary, the compound obtained from bioconjugation reaction 1 was purified by Sephadex® with buffer 2. The fractions containing the purified compound (NanoDrop assay) were pooled and then concentrated by Vivaspin® (10 kDa). On the concentrated solution, a buffer exchange was performed by Vivaspin® (10 kDa) to obtain the compound that was used in buffer 1 in the next step.
[0206] Bioconversion reaction 2
[0207] The optionally purified compound obtained from bioconjugation reaction 1 (1.0 eq) was placed under argon. The reducing agent (7.0-30.0 eq, preferably 8.0-15.0 eq) was then added and the reaction medium was incubated at 37 °C for 2 h. Then the solution of compound (Ha), (Ilb), (Ile), (Ild), or (IV) (5.0-30.0 eq, preferably 12.0-15.0 eq) was added under argon and the reaction medium was stirred at 37 °C for 2 h 30 min.
[0208] Bioconversion reaction 2'
[0209] The optionally purified compound obtained from bioconjugation reaction 1 (1.0 eq) was placed under argon. The solution of the compound of formula (Ha), (Ilb), (Ile), (Ild), or (IV) (5.0-30.0 eq, preferably 12.0-15.0 eq) and the reducing agent solution (7.0-30.0 eq, preferably 8.0-15.0 eq) were added and the reaction medium was stirred under argon at 37 °C for 1 to 5 h, preferably 2 h 30 min.
[0210] Purification 2
[0211] If necessary, the compound obtained from the 2, 2' bioconjugation reaction or from the one-step click reaction (see below) was purified by Sephadex® with buffer 2. The fractions containing the purified compound (NanoDrop® assay) were pooled for use in the next step.
[0212] Click reaction
[0213] In one step: addition of a single compound (III) or concomitant addition of two compounds (III) To the optionally purified compound obtained at the end of the bioconjugation reaction 2 or 2' (1.0 eq) was added the solution(s) of the compound(s) (III) (5.0-30.0 eq, preferably 15.0-30.0 eq) and the reaction medium was stirred at 25°C or 37°C for at least 16 h.
[0214] In two steps: sequential addition of two compounds (III)
[0215] To the optionally purified compound obtained at the end of the bioconjugation reaction 2 or 2' (1.0 eq) was added a solution of the first compound (III) (5.0-30.0 eq, preferably 15.0-30.0 eq) and the reaction medium was stirred at 37 °C or 25 °C for at least 16 h. The intermediate compound obtained is optionally purified (see below). Then a solution of the second compound (III) was added (5.0-30.0 eq, preferably 15.0-30.0 eq) and the reaction medium was stirred at 37 °C or 25 °C for at least 16 h.
[0216] Purification 3
[0217] When two click reactions were carried out sequentially, the compound obtained at the end of the first click reaction was advantageously purified by Sephadex® with buffer 2. The fractions containing the purified compound (dosage by NanoDrop®) were pooled and then concentrated by Vivaspin® (10 kDa) to be used in the second click reaction.
[0218] Examples
[0219] Example 1: 4-nitrophenyl l-[4-(6-methyl-l,2,4,5-tetrazin-3-yl)phenoxy]- 3,6,9,12-tetraoxapentadecan-15-oate (1)
[0220] [Chem40]
[0221] 4-Methylteatrazinylphenoxy-3,6,9,12-tetraoxapentadecan-15-oic acid (12.2 mg; 0.028 mmol; 1.0 eq) was dissolved in anhydrous DMF (250 μL) and then 4-nitrophenol (5.1 mg; 0.036 mmol; 1.3 eq), DCC (7.5 mg; 0.036 mmol; 1.3 eq) and DMAP (1.0 mg; 0.008 mmol; 0.3 eq) were added. The reaction medium was stirred under argon at RT for 18 h 30 min. The mixture was purified by semi-preparative high-pressure liquid chromatography (t R= 26.01 min; on the Gilson PLC 2050 system [ARMEN V2 (pump) and ECOM TOYDAD600 (UV detector)] UV detection at 254 nm at 25 °C; Waters XBridge™ C-18 column; 5 μm (250 mm x 19.00 mm); elution performed with 0.1% TFA (by volume) in water (solvent A), and MeCN (solvent B); gradient 20 to 100% B over 32 min then 100% B over 6 min at 17.1 mL / min) to give (1) (7.8 mg; 50%) as a pink oil.
[0222] NMR (300 MHz, CD3OD) 5 8.53 - 8.42 (m; 2H); 8.32 - 8.21 (m; 2H); 7.42 - 7.31 (m; 2H); 7.21 - 7.11 (m; 2H); 4.29 - 4.20 (m; 2H); 3.93 - 3.80 (m; 4H); 3.75 - 3.66 (m; 4H); 3.66 - 3.63 (m; 8H); 3.00 (s; 3H); 2.87 (t; J= 6.0 Hz; 2H). SMHR (ESI): m / z calculated for C26H32N5O9[M+H] + : 558.2195; observed 558.2203.
[0223] Example 2: (2R)-2-[(2S)-2-[(S)-[(2R)-l-[(3S,4R,5R)-4-[(2R)-N,3-dimethyl-2-[(2R)-3-methyl-2-{N-methyl-l-[4-(6-methyl-l,2,4,5-tetrazin-3-yl)phenoxy]-3,6,9,12-tetraoxapentadecan-15-amido}butanamido] butanamido]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl](methoxy)methyl]propanamido]-3-phenylpropanoic acid (2)
[0224] [Chem41]
[0225] To a solution of HOBt (2.0 mg; 0.0151 mmol; 2.1 eq), solubilized in anhydrous DMF (100 pL) in the presence of anhydrous DIPEA (2.5 pL; 0.0144 mmol; 2.0 eq) was added 4-nitrophenyl l-[4-(6-methyl-l,2,4,5-tetrazin-3-yl)phenoxy]-3,6,9,12-tetraoxapentadecan-15-oate (1) (7.1 mg; 0.0128 mmol; 1.8 eq). Then a solution of MMAF trifluoroacetic acid salt (6.1 mg; 0.0072 mmol; 1.0 eq), solubilized in anhydrous DMF (100 μL), was added to the reaction medium under stirring, under argon at 25°C for 19 h. The mixture was purified by semi-preparative high-pressure liquid chromatography (t R= 27.44 min; on the Gilson PLC 2050 system [ARMEN V2 (pump) and ECOM TOYDAD600 (UV detector)J UV detection at 254 nm at 25 °C; Waters XBridge™ C-18 column; 5 μm (250 mm x 19.00 mm); elution carried out with 0.1% TFA (by volume) in water (solvent A), and MeCN (solvent B); gradient 20 to 90% B over 32 min then 90% B over 6 min at 17.1 mL / min) to give (2) (1.4 mg; 17%) as a purple oil.
[0226] NMR J H (300 MHz, CD3OD) 5 8.57 - 8.45 (m; 2H); 8.41 - 8.08 (m; 1H); 8.08 - 7.79 (m; 1H); 7.37 - 7.06 (m; 8H); 4.78 - 4.59 (m; 1H); 4.32 - 4.22 (m; 2H); 4.14 - 3.96 (m; 2H); 3.96 - 3.85 (m; 2H); 3.84 - 3.52 (m; 13H); 3.48 - 3.35 (m; 5H); 3.21 - 3.15 (m; 2H); 3.14 - 3.03 (m; 4H); 3.00 (s; 3H); 2.97 - 2.89 (m; 1H); 2.83 - 2.63 (m; 1H); 2.61 - 2.40 (m; 2H); 2.41 - 2.15 (m; 2H); 2.15 - 1.67 (m; 8H); 1.50 - 1.12 (m; 3H); 1.12 - 0.76 (m; 28H).
[0227] SMHR (ESI): m / z calculated for C59H92N9O1 [M+H] + : 1150.6758; observed 1150.6754. The commercial compounds, and those from application WO 2022 / 018371 or application WO 2020 / 234541, used for the bioconjugation reactions are summarized in Table 1 below.
[0228] Table 1
[0229]
[0230] Example 3: Compound (14): Trastuzumab - compound (6) clicked compound (10) - compound (7) clicked compound (9)
[0231] Step al
[0232] Reagents
[0233] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (7.0 eq), compound (6) (10.6 eq) at a concentration of 1 mM in a mixture of 80% DMF and 20% MeOH.
[0234] Method
[0235] Bioconjugation reaction 1 at 37°C.
[0236] Step bl)
[0237] Reagents
[0238] Compound from al) at 3.2 mg / mL in buffer 1, reducing agent (8.0 eq) and compound (7) (15.0 eq) at a concentration of 10 mM in MeOH.
[0239] Method
[0240] Bioconjugation reaction 2 at 37°C.
[0241] Step cl)
[0242] Reagents
[0243] Compound from bl) at 2.6 mg / mL in buffer 1, compound (9) (16.5 eq) and compound (10) (11.6 eq) at a concentration of 10 mM in DMSO.
[0244] Method Click reaction at 25 °C for 17 h. In this case, compounds (9) and (10) were added concomitantly. A mixture of conjugates was obtained, the HRMS analysis below of which determined the majority presence of conjugate (14): DAR 1 compound (6) clicked with compound (10) and DAR 1 compound (7) clicked with compound (9), the structure of which is as shown in Figure 1A.
[0245] Denaturing HRMS analysis
[0246] The results are presented in Table 2 below.
[0247] Table 2
[0248] Example 4: Compound (14): Trastuzumab - compound (3) clicked compound (2) - compound (11)
[0249] Step a T)
[0250] Reagents
[0251] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (7.0 eq), compound (3) (10.6 eq) at a concentration of 1 mM in a mixture of 80% DMF and 20% MeOH. Method
[0252] Bioconjugation reaction 1 then purification 1 at 37°C.
[0253] Step b2)
[0254] Reagents
[0255] Compound from al) at 5.0 mg / mL in buffer 1, reducing agent (15.0 eq) and compound (11) (15.0 eq) at a concentration of 2 mM in a mixture of 80% DMF and 20% MeOH.
[0256] Method
[0257] Bioconjugation reaction 2 at 37°C then purification 2.
[0258] Step c2)
[0259] Reagents
[0260] Compound from b2) at 1.3 mg / mL in buffer 2 and compound (2) (15.0 eq) at a concentration of 1 mM in DMSO.
[0261] Method
[0262] Click reaction at 25°C for 23 h then purification 2. A mixture of conjugates was obtained whose HRMS analysis below made it possible to determine the majority presence of conjugate (15): DAR 1 compound (3) clicked with compound (2) and DAR 2 compound (11) whose structure is as shown in Figure 1B.
[0263] Denaturing HRMS analysis
[0264] The results are presented in Table 3 below.
[0265] Table 3
[0266] Example 5: Compound (16): Trastuzumab - compound (3) clicked compound (2) - compound (12)
[0267] Step al)
[0268] Reagents
[0269] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (7.0 eq), compound (3) (10.6 eq) at a concentration of 1 mM in a mixture of 80% DMF and 20% MeOH.
[0270] Method
[0271] Bioconjugation reaction 1 at 37°C then purification 1.
[0272] Step b2)
[0273] Reagents
[0274] Compound from al) at 5.0 mg / mL in buffer 1, reducing agent (15.0 eq) and compound (12) (15.0 eq) at a concentration of 2 mM in DMSO.
[0275] Method
[0276] Bioconjugation reaction 2 at 37°C then purification 2.
[0277] Step c2)
[0278] Reagents
[0279] Compound from b2) at 0.7 mg / mL in buffer 2 and compound (2) (15.0 eq) at a concentration of 1 mM in DMSO.
[0280] Method
[0281] Click reaction at 25°C for 23 h then purification 2. A mixture of conjugates was obtained whose HRMS analysis below made it possible to determine the majority presence of conjugate (16): DAR 1 compound (3) clicked with compound (2) and DAR 4 compound (12) whose structure is as shown in Figure 1C.
[0282] Denaturing HRMS analysis
[0283] The results are presented in Table 4 below. Table 4
[0284] Example 6: Compound (17): Trastuzumab - compound (3) clicked compound (2) - compound (13)
[0285] Step al
[0286] Reagents
[0287] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (7.0 eq), compound (3) (10.6 eq) at a concentration of 1 mM in a mixture of 80% DMF and 20% MeOH.
[0288] Method
[0289] Bioconjugation reaction 1 at 37°C then purification 1.
[0290] Step b2)
[0291] Reagents
[0292] Compound from al) at 5.0 mg / mL in buffer 1, reducing agent (15.0 eq) and compound (13) (15.0 eq) at a concentration of 2 mM in DMF.
[0293] Method
[0294] Bioconjugation reaction 2 at 37°C then purification 2.
[0295] Step c2)
[0296] Reagents
[0297] Compound from b2) at 0.9 mg / mL in buffer 2 and compound (2) (15.0 eq) at a concentration of 1 mM in DMSO.
[0298] Method
[0299] Click reaction at 25°C for 23 h then purification 2. A mixture of conjugates was obtained whose HRMS analysis below made it possible to determine the majority presence of the conjugate (17): DAR 1 compound (3) clicked with compound (2) and DAR 1 compound (13) whose structure is as shown in Figure 1A.
[0300] Denaturing HRMS analysis
[0301] The results are presented in Table 5 below.
[0302] Table 5 Example 7: Compound (18): Trastuzumab - compound (3) clicked compound (8) - compound (4) clicked compound (2)
[0303] Step al
[0304] Reagents
[0305] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (7.0 eq), compound (3) (10.6 eq) at a concentration of 1 mM in a mixture of 80% DMF and 20% MeOH. Method
[0306] Bioconjugation reaction 1 at 37°C then purification 1.
[0307] Step bl)
[0308] Reagents
[0309] Compound from al) at 5.0 mg / mL in buffer 1, reducing agent (15.0 eq) and compound (4) (15.0 eq) at a concentration of 2 mM in DMF.
[0310] Method
[0311] Bioconjugation reaction 2 at 37°C then purification 2.
[0312] Step cl)
[0313] Reagents
[0314] Compound from bl) at 0.6 mg / mL in buffer 2, compound (8) (15.0 eq) at a concentration of 1 mM in DMSO (“click 1”), then compound from “click 1” at 1.8 mg / mL in buffer 2, compound (2) (15.0 eq) at a concentration of 2 mM in DMSO (“click 2”).
[0315] Method
[0316] Sequential click.
[0317] Click 1: click reaction at 37°C for 23 h then purification 3.
[0318] Click 2: Click reaction at 37°C for 18 h. A mixture of conjugates was obtained, the HRMS analysis below of which determined the majority presence of conjugate (18): DAR 1 compound (3) clicked with compound (8) and DAR 1 compound (4) clicked with compound (2) whose structure is as shown in Figure 1A. Denaturing HRMS analysis
[0319] The results are presented in Table 6 below.
[0320] Table 6 Example 8: Compound (19): Trastuzumab - compound (3) clicked compound (2) - compound (5) clicked compound (8)
[0321] Step al
[0322] Reagents
[0323] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (7.0 eq), compound (3) (10.6 eq) at a concentration of 1 mM in a mixture of 80% DMF and 20% MeOH. Method
[0324] Bioconjugation reaction 1 at 37°C then purification 1.
[0325] Step bl)
[0326] Reagents
[0327] Compound from al) at 5.0 mg / mL in buffer 1, reducing agent (15.0 eq) and compound (5) (15.0 eq) at a concentration of 2 mM in DMF.
[0328] Method
[0329] Bioconjugation reaction 2 at 37°C then purification 2.
[0330] Step cl)
[0331] Reagents
[0332] Compound from bl) at 1.0 mg / mL in buffer 2 and compound (2) (15.0 eq) at a concentration of 1 mM in DMSO (“click 1”), then compound from “click 1” at 1.2 mg / mL in buffer 2 and compound (8) (15.0 eq) at a concentration of 1 mM in DMSO (“click 2”).
[0333] Method
[0334] Sequential click.
[0335] Click 1: click reaction at 25°C for 23 h then purification 3.
[0336] Click 2: Click reaction at 37°C for 18 h. A mixture of conjugates was obtained, the HRMS analysis below of which determined the majority presence of conjugate (19): DAR 1 compound (3) clicked with compound (2) and DAR 1 compound (5) clicked with compound (8) whose structure is as shown in Figure 1A. Denaturing HRMS analysis
[0337] The results are presented in Table 7 below.
[0338] Table 7 Example 9: Compound (21): Trastuzumab - compound (3) - compound (20) clicked compound (13)
[0339] Step al
[0340] Reagents
[0341] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (4.0 eq), compound (3) (3.0 eq) at a concentration of 1 mM in a mixture of 80% DMF and 20% MeOH.
[0342] Method
[0343] Bioconjugation reaction 1 at 37°C then purification 1.
[0344] Step b2)
[0345] Reagents
[0346] Compound from al) at 2.3 mg / mL in buffer 1, reducing agent (15.0 eq) and compound (13) (15.0 eq) at a concentration of 1 mM in a mixture of 20% MeOH and 80% DMF.
[0347] Method
[0348] 2' bioconjugation reaction for 2.5 hours at 37°C.
[0349] Step c2)
[0350] Reagents
[0351] Compound from b2) at 1.5 mg / mL in buffer 1, compound (20) (30.0 eq) at a concentration of 10 mM in DMSO.
[0352] Method
[0353] Click reaction at 37 °C for 24 h. A mixture of conjugates was obtained, the HRMS analysis below of which determined the majority presence of conjugate (21): DAR 1 compound (3) clicked with compound (20) and DAR 1 compound (13) whose structure is as shown in Figure 1A.
[0354] Denaturing HRMS analysis
[0355] The results are presented in Table 8 below.
[0356] Table 8
[0357] Example 10: Compound (22): Trastuzumab - compound (3) clicked compound (20)
[0358] - compound (11)
[0359] Step al)
[0360] Reagents Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (4.0 eq), compound (3) (3.0 eq) at a concentration of 1 mM in a mixture of 80% DMF and 20% MeOH.
[0361] Method
[0362] Bioconjugation reaction 1 at 37°C then purification 1.
[0363] Step b2)
[0364] Reagents
[0365] Compound from al) at 2.3 mg / mL in buffer 1, reducing agent (15.0 eq) and compound (11) (15.0 eq) at a concentration of 1 mM in a mixture of 20% MeOH and 80% DMF.
[0366] Method
[0367] 2' bioconjugation reaction for 2.5 hours at 37°C.
[0368] Step c2)
[0369] Reagents
[0370] Compound from b2) at 1.5 mg / mL in buffer 1, compound (20) (30.0 eq) at a concentration of 10 mM in DMSO.
[0371] Method
[0372] Click reaction at 37 °C for 24 h. A mixture of conjugates was obtained, the HRMS analysis below of which determined the majority presence of conjugate (22): DAR 1 compound (3) clicked with compound (20) and DAR 2 compound (11) whose structure is as shown in Figure 1B.
[0373] Denaturing HRMS analysis
[0374] The results are presented in Table 9 below.
[0375] Table 9
[0376] Example 11: Compound (23): Trastuzumab - compound (3) clicked compound (20) - compound (12)
[0377] Step al)
[0378] Reagents
[0379] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (4.0 eq), compound (3) (3.0 eq) at a concentration of 1 mM in a mixture of 80% DMF and 20% MeOH.
[0380] Method
[0381] Bioconjugation reaction 1 (for 2.5 hours) at 37°C then purification 1. Step b2)
[0382] Reagents
[0383] Compound from al) at 2.3 mg / mL in buffer 1, reducing agent (15.0 eq) and compound (12) (20.0 eq) at a concentration of 1 mM in a mixture of 20% MeOH and 80% DMF.
[0384] Method
[0385] 2' bioconjugation reaction for 2.5 hours at 37°C.
[0386] Step c2)
[0387] Reagents
[0388] Compound from b2) at 1.5 mg / mL in buffer 1, compound (20) (30.0 eq) at a concentration of 10 mM in DMSO.
[0389] Method
[0390] Click reaction at 37 °C for 24 h. A mixture of conjugates was obtained, the HRMS analysis below of which determined the majority presence of conjugate (23): DAR 1 compound (3) clicked with compound (20) and DAR 4 compound (12) the structure is as shown in Figure 1C.
[0391] Denaturing HRMS analysis
[0392] The results are presented in Table 10 below.
[0393] Table 10
[0394] Example 12: Compound (24): Trastuzumab - compound (13) - compound (3) clicked compound (8)
[0395] Step a2)
[0396] Reagents
[0397] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (7.0 eq), compound (13) (4.0 eq) at a concentration of 1 mM in a mixture of 80% DMF and 20% MeOH.
[0398] Method
[0399] Bioconjugation reaction 1 for 1 h at 37°C then purification 1.
[0400] Step b5)
[0401] Reagents
[0402] Compound from a2) at 2.3 mg / mL in buffer 1, reducing agent (15.0 eq) and compound (3) (15.0 eq) at a concentration of 1 mM in a mixture of 20% MeOH and 80% DMF. Method
[0403] 2' bioconjugation reaction, for 2.5 hours at 37°C.
[0404] Step c5)
[0405] Reagents
[0406] Compound from b5) at 1.5 mg / mL in buffer 1, compound (8) (5.0 eq) at a concentration of 10 mM in DMSO.
[0407] Method
[0408] Click reaction at 25 °C for 17 h. A mixture of conjugates was obtained, the HRMS analysis below of which determined the majority presence of conjugate (24): DAR 1 compound (13) and DAR 1 compound (3) clicked with compound (8) whose structure is as shown in Figure 1A.
[0409] Denaturing HRMS analysis
[0410] The results are presented in Table 11 below.
[0411] Table 11
[0412] Example 13: Compound (25): Trastuzumab - compound (4) clicked compound (2) - compound (12)
[0413] Step al)
[0414] Reagents
[0415] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (3.0 eq), compound (4) (4.0 eq) at a concentration of 1 mM in DMF.
[0416] Method
[0417] Bioconjugation reaction 1 at 25°C then purification 1.
[0418] Step b2)
[0419] Reagents
[0420] Compound from al) at 5.1 mg / mL in buffer 1, reducing agent (12.0 eq) and compound (12) (15.0 eq) at a concentration of 2 mM in DMSO.
[0421] Method
[0422] Bioconjugation reaction 2.
[0423] Step c2)
[0424] Reagents Compound from b2) at 3.1 mg / mL in buffer 1, compound (2) (10.0 eq) at a concentration of 2 mM in DMSO.
[0425] Method
[0426] Click reaction at 25 °C for 16 h. A mixture of conjugates was obtained, the HRMS analysis below of which determined the majority presence of conjugate (25): DAR 1 compound (4) clicked with compound (2) and DAR 4 compound (12), the structure of which is as shown in Figure 1C.
[0427] Denaturing HRMS analysis
[0428] The results are presented in Table 12 below.
[0429] Table 12
[0430] Example 14: Compound (26): Trastuzumab - compound (4) clicked compound (2) - compound (11)
[0431] Step al)
[0432] Reagents
[0433] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (3.0 eq), compound (4) (4.0 eq) at a concentration of 1 mM in DMF.
[0434] Method
[0435] Bioconjugation reaction 1 at 25°C then purification 1.
[0436] Step b2)
[0437] Reagents
[0438] Compound from al) at 5.1 mg / mL in buffer 1, reducing agent (12.0 eq) and compound (11) (15.0 eq) at a concentration of 2 mM in a mixture of 80% MeOH and 20% DMF.
[0439] Method
[0440] Bioconjugation reaction 2.
[0441] Step c2)
[0442] Reagents
[0443] Compound from b2) at 4.3 mg / mL in buffer 1, compound (2) (10.0 eq) at a concentration of 2 mM in DMSO.
[0444] Method Click reaction at 25 °C for 16 h. A mixture of conjugates was obtained, the HRMS analysis below of which determined the majority presence of conjugate (26): DAR 1 compound (4) clicked with compound (2) and DAR 2 compound (11), the structure of which is as shown in Figure 1B.
[0445] Denaturing HRMS analysis
[0446] The results are presented in Table 13 below.
[0447] Table 13
[0448] Example 15: Compound (27): Trastuzumab - compound (4) clicked compound (2) - compound (13)
[0449] Step al)
[0450] Reagents
[0451] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (3.0 eq), compound (4) (4.0 eq) at a concentration of 1 mM in DMF.
[0452] Method
[0453] Bioconjugation reaction 1 at 25°C then purification 1.
[0454] Step b2)
[0455] Reagents
[0456] Compound from al) at 5.1 mg / mL in buffer 1, reducing agent (12.0 eq) and compound (13) (15.0 eq) at a concentration of 2 mM in a mixture of 80% MeOH and 20% DMF.
[0457] Method
[0458] Bioconjugation reaction 2.
[0459] Step c2)
[0460] Reagents
[0461] Compound from b2) at 4.3 mg / mL in buffer 1, compound (2) (10.0 eq) at a concentration of 2 mM in DMSO.
[0462] Method
[0463] Click reaction at 25 °C for 16 h. A mixture of conjugates was obtained, the majority presence of conjugate (27) being determined by the HRMS analysis below: DAR 1 compound (4) clicked with compound (2) and DAR 1 compound (13), the structure of which is as shown in Figure 1A. Denaturing HRMS analysis
[0464] The results are presented in Table 14 below.
[0465] Table 14
[0466] Example 16: Compound (28): Trastuzumab - compound (4) clicked compound (2) - compound (5) clicked compound (8)
[0467] Step al)
[0468] Reagents
[0469] Trastuzumab at 5.0 mg / mL in buffer 1, reducing agent (3.0 eq), compound (4) (4.0 eq) at a concentration of 1 mM in DMF.
[0470] Method
[0471] Bioconjugation reaction 1 at 25°C then purification 1.
[0472] Step b3)
[0473] Reagents
[0474] Compound from al) at 4.7 mg / mL in buffer 1, compound (2) (6.0 eq) at a concentration of 2 mM in DMSO.
[0475] Method
[0476] Click reaction at 25°C for 16 h.
[0477] Step c4)
[0478] Reagents
[0479] Compound from b3) at 4.7 mg / mL in buffer 1, reducing agent (10.0 eq) and compound (5) (12.0 eq) at a concentration of 2 mM in DMF.
[0480] Method
[0481] Bioconjugation reaction 2.
[0482] Step dl)
[0483] Reagents
[0484] Compound from c4) at 2.0 mg / mL in buffer 1, compound (8) (10.0 eq) at a concentration of 2 mM in DMSO.
[0485] Method
[0486] Click reaction at 25°C for 16 h.
[0487] A mixture of conjugates was obtained, the HRMS analysis below of which made it possible to determine the majority presence of conjugate (28): DAR 1 compound (4) clicked with compound (2) and DAR 1 compound (5) clicked with compound (8), the structure of which is as shown in Figure 1A.
[0488] Denaturing HRMS analysis
[0489] The results are presented in Table 15 below. Table 15
Claims
DEMANDS 1. A process for preparing a mixture of antibody-drug conjugates comprising predominantly either a conjugate of structure (A) as shown in Figure 1A, or a conjugate of structure (B) as shown in Figure 1B, or a conjugate of structure (C) as shown in Figure 1C; structures in which: i) the symbol • represents a binding head of formula (Ha), (Ilb), (Ile) or (Ild): O (Ha) - T represents -(CH2) y - , where y is an integer from 0 to 6; - W is -ORa, -COR2, -CONR3R4 OR -NR3COR4; - R a is -(CH2CH2O) q -(CH2) r -R5, -(CR c R d -R5, -COR b , -(CR c R d ) r -NHCO-(CH2CH2O) q -(CH2) r -R5, -(CR c R d ) r -CONH-(CH2CH2O) q -(CH2) r -R5, -(CH2CH2O) q -(CH2) r -NHCO-(CRc R d ) r -R5ou -(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R5; Rb is -(CH2CH2O) q -(CH2) r -R5, -O(CH2CH2O) q -(CH2) r -R5, -(CR c R d -R5, -O(CR c R d X-R5, -(CR c R d ) r -NHCO-(CH2CH2O) q -(CH2) r -R5, -(CR c R d ) r -CONH-(CH2CH2O) q -(CH2) r - R5, -(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R5ou -(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R5; - R2est -(CH2CH2O) q -(CH2) r -R5, -(CR c R d ) r -R5, -O(CH2CH2O) q -(CH2) r -R5, -O(CR c R d ) r -R5, -O(CR c R d ) r-NHCO-(CH2CH2O) q -(CH2) r -R5, -O(CR c R d ) r -CONH-(CH2CH2O) q -(CH2) r -R5, -O(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R5ou -O(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R5; - R3est -H, -(C1-C6)alkyle ou -(CH2) V -SO3H, de préférence R3est -H ou -(C1-C6)alkyle ; - R4est -(CH2CH2O) q R5, -(CR c R d ) r R5, -(CR c R d ) r -NHCO-(CH2CH2O) q -R5, -(CR c R d ) r -CONH-(CH2CH2O) q -R5, -(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R5, -(CH2CH2O) q - (CH2) r -CONH-(CR c R d ) r -R5, -CH-[(CR c R d ) r -CONH-(CR c R d) r -(OCH2CH2) q -R5]2, -CH-[(CR c R d ) r - NHCO-(CR c R d ) r -(OCH2CH2) q -R5]2, -CH-[(CR c R d ) r -CONH-(CR c R d ) r -R5]2, or -CH-[(CR c R d ) r - NHCO-(CR c R d ) r -R5]2, preferably R4est -(CH2CH2O) q R5, -(CR c R d ) r R5, -(CR c R d ) r -NHCO-(CH2CH2O) q -R5, -(CR c R d ) r <ONH-(CH2CH2O) q -R5, -(CH2CH2O) q - (CH2) r -NHCO-(CR c R d ) r -R5, or -(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R5; - each R5est -(CH2) s R6; - each R6 is chosen from: - R cis H; - each R d is chosen from -H, -CH2-SO3H or -SO3H; - R7 is -H or -CH3; - each q is an integer from 1 to 24; - each r is an integer ranging from 1 to 8; - each s is an integer ranging from 0 to 6; - each v is an integer from 1 to 6; ii) the symbol represents a connecting arm which is a direct connection; a bridge -SS-; or a group of formulas -R11-(A) Z - - Ru is a direct bond, an R6-(CR) group c R d ) r -CO-, R6-(CH2CH2O) q -(CH2) s -CO-, or R6-CCR c R d X-NH-, where R6, R c , R d , q, r and s are as defined above; - A is an amino acid residue; - z is equal to 1, 2, 3, 4 or 5; iii) the symbol represents a spacer which is a direct link or a formula group: - G is a sulfate, a sugar, a glucuronide, or a galactoside, said sugar being a saccharide group preferably selected from a beta-glucuronic acid, a beta-D-galactose, a beta-D-glucose, an alpha-D-mannose, an N-acetyl-D-glucosaminyl, an N-acetyl-D-galactosaminyl, a D-glucuronyl, an L-iduronyl, a D-glucopyranosyl, a D-galactopyranosyl, a D-mannopyranosyl or an L-fucopyranosyl, preferably G is a sulfate, a beta-glucuronic acid, or a beta-D-galactose; - Ri2 is -H or -NO2; and iv) M is a molecule of interest; it being understood that: each conjugate comprises at least one binding head of formula (Ha) or (Ilb), in each of the aforementioned conjugates, at least one of the linker arm and spacer is present; said process comprising: a) the reaction of an antibody with a compound of formula (II'a) or (ITb): bl) the reaction of the compound obtained in step a1) with a compound of formula (II'a) or (II'b) as defined above, or with a compound of formula (II'c) or (II'd): in which T and W are as defined above; it being understood that: - if a compound (II'a) is used in step a1) and a compound (II'a) is used in step b1), the two compounds (II'a) have a different structure; - if a compound (Il'b) is used in step a1) and a compound (Il'b) is used in step b1), the two compounds (Il'b) have a different structure; c1) the reaction of the compound obtained in step b1) with two identical or different compounds, each corresponding to formula (III): in which: and s are as defined above; - the connecting arm, the spacer, and M are as defined below- above, M being identical or not in each compound (III); or a1) the reaction of an antibody with a compound of formula (II'a) or (II'b); b2) the reaction of the compound obtained in step a1) with a compound of formula (IV): in which: i) the hook head is a compound of formula (II"a), (II"b), (II"c), or (II"d): - T is as defined above; - Y is “OR'a, -COR'2, -CONR'3R^ or -NR'3COR^ , - R' a is -(CH2CH2O) q -(CH2) r -R'5, -(CR c R d ) r -R'5, -COR' b , -(CR c R d ) r -NHCO-(CH2CH2O) q -(CH2) r - R'5, -(CR c R d ) r -CONH-(CH2CH2O) q -(CH2) r -R'5, -(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R'5 or -(CH2CH2O) q -(CH2) r -CONH-(CR c Rd ) r -R'5; R' b est -(CH2CH2O) q -(CH2) r -R'5, -O(CH2CH2O) q -(CH2) r -R'5, -(CR c RJr-R'5, -O(CR c R d ) r -R'5, -(CR c R d ) r -NHCO-(CH2CH2O) q -(CH2) r -R'5, -(CR c R d ) r -CONH-(CH2CH2O) q -(CH2) r - R'5, -(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R'5OU -(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R'5; - R'2est -OH, -(CH2CH2O) q -(CH2) r -R'5, -(CR c R d ) r -R'5, -O(CH2CH2O) q -(CH2) r -R'5, -OCCR c R d ),- R'5, -O(CR c R d ) r -NHCO-(CH2CH2O) q -(CH2) r -R'5, -O(CR c R d ) r-CONH-(CH2CH2O) q -(CH2) r -R'5, -O(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R'5ou -O(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R'5; - R3est -H, -(C1-C6)alkyle ou -(CH2) V -SO3H, de préférence R3est -H ou -(C1-C6)alkyle ; R4est -(CH2CH2O) q R'5, -(CR c RJrR'5, -(CR c R d ) r -NHCO-(CH2CH2O) q -R'5, -(CR c R d ) r -CONH-(CH2CH2O) q -R'5, -(CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R'5, -(CH2CH2O) q - (CH2) r -CONH-(CR c R d ) r -R'5, -CH-[(CR c R d ) r -CONH-(CR c R d ) r -(OCH2CH2) q -R'5]2, -CH-[(CR c R d ) r - NHCO-(CR c Rd ) r -(OCH2CH2) q -R'5]2, -CH-[(CR c R d ) r -CONH-(CR c R d ) r -R'5]2, ou -CH-[(CR c R d ) r - NHCO-(CR c R d ) r -R'5]2, de préférence R'4est -(CH2CH2O) q R'5, -(CR c R d ) r R'5, -(CR c R d ) r -NHCO-(CH2CH2O) q -R'5, -(CR c R d ) r -CONH-(CH2CH2O) q -R'5, (CH2CH2O) q -(CH2) r -NHCO-(CR c R d ) r -R'5, OU -(CH2CH2O) q -(CH2) r -CONH-(CR c R d ) r -R'5; - chaque R'5est -(CH2) S R'6ou -(CH2) S R'7; - R'6est choisi parmi : - R'7est -COOH ou -NR'gR'g ; - R'8est -H ou -(C1-C6)alkyle ; - R'9 is -H or -(C1-C6)alkyl; - R'IO is -H or -CH3; - R c , R d , q, r and s are as defined above; and ii) the connecting arm is a direct connection; an -SS- bridge; or a formula -R' group 11 -(HAS) Z - ; - R' 11 - is a direct bond, an R'6-(CR) group c R d ) r -CO-, R'6-(CH2CH2O) q -(CH2) s -CO-, or R'6-(CR c R d ) r -NH-, where R'6-, R c , R d , q, r and s are as defined above; - A is an amino acid residue; - z is equal to 1, 2, 3, 4 or 5; and iii) the spacer and M are such as defined in step cl), it being understood that the bonding arm and the spacer cannot simultaneously be a direct bond; c2) the reaction of the compound obtained in step b2) with a compound of formula (III) as defined in step cl), the molecule of interest M of compound (III) being identical to or different from the molecule of interest M of compound (IV); or a1) the reaction of an antibody with a compound of formula (II'a) or (II'b); b3) the reaction of the compound obtained in step a1) with a compound of formula (III) as defined above; c3) the reaction of the compound obtained in step b3) with a compound of formula (IV) as defined above, the molecule of interest M of compound (IV) being identical to or different from the molecule of interest M of compound (III); or a1) the reaction of an antibody with a compound of formula (II'a) or (II'b); b3) the reaction of the compound obtained in step a1) with a compound of formula (III) as defined above; c4) the reaction of the compound obtained in step b3) with a compound of formula (II'a), (II'b), (II'c) or (II'd) as defined above; dl) the reaction of the compound obtained in step c4) with a compound of formula (III) as defined above, the molecule of interest M being identical or not in each compound (III).
2. A preparation method according to claim 1, comprising steps a1), b1) and c1).
3. A preparation method according to claim 2, wherein the hook head used in step a1) corresponds to one of formulas (II'a) or (II'b), and the hook head used in step b1) corresponds to one of formulas (II'a), (II'b), (II'c) or (II'd) in which: - W is -CONR3R4 OR -NR3COR4, preferably W is -CONR3R4; - R3 is -H or -(C1-C6)alkyl; - R4est -(CH2CH2O)q-(CH2) r -R5, or -(CR c R d ) r -R5; - each R5est -(CH2) S R6; - R6est is chosen from: REPLACEMENT SHEET (RULE 26) - R c , R d are as defined in claim 1; - q is an integer from 1 to 12, preferably q is an integer from 1 to 8; - r is an integer ranging from 1 to 6.
4. Preparation method according to claim 3, wherein the hook head is a compound of formula (II'a1l), (II'a2), (II'a3), (II'a4), (II'a5), or (II'a6):
5. Preparation method according to claim 1, which includes steps a1), b2) and c2).
6. A preparation method according to claim 5, wherein the hook head used in step b2) conforms to one of the formulas (II"a), (II"b), (II"c) or (II"d) in which: - Y is -CONR'3R'4 OR -NR'3COR'4, preferably Y is -CONR'3R'4; - R'3 is -H or -(C1-C6)alkyl; - R'4est -(CH2CH2O)q _ (CH2) r -R'5, or -(CR c R d ) r -R'5 - R'5est _ (CH2) S R'6 - R'6est is chosen from: - R c , R d are as defined in claim 1; - q is an integer from 1 to 12, preferably q is an integer from 1 to 8; - r is an integer ranging from 1 to 6.
7. Preparation method according to claim 6, wherein the hook head is a compound of formula (IT'al), (II"a2), (II"a3), (II"a4), (II"a5), (II"a6), (II"a7), (II"a8) or (II'bl):
8. A method for preparing a mixture of antibody-drug conjugates comprising predominantly either a structural conjugate (A), a structural conjugate (B), or a structural conjugate (C), these structures being as defined in claim 1, which comprises: a2) the reaction of an antibody with a compound of formula (IV) as defined in claim 1, wherein the hook head is solely a compound of formula (II"a) or (II"b); b4) the reaction of the compound obtained in step a2) with a compound of formula (IV) as defined in claim 1, M being identical or not in each compound (IV), it being understood that: - if a compound (II"a) is used in step a2) and a compound (II"a) is used in step b4), the two compounds (II"a) have a different structure; - if a compound (II"b) is used in step a2) and a compound (II"b is used in step b4), the two compounds (II"b) have a different structure; or a2) the reaction of an antibody with a compound of formula (IV) as defined in claim 1, wherein the hook head is solely a compound of formula (II"a) or (II"b); b5) the reaction of the compound obtained in step a2) with a compound of formula (II'a), (ITb), (II'c) or (II'd) as defined in claim 1; c5) the reaction of the compound obtained in step b5) with a compound of formula (III) as defined in claim 1, the molecule of interest M of compound (III) being identical to or different from the molecule of interest M of compound (IV).
9. A preparation method according to any one of the preceding claims, wherein the bonding arm is a direct bond or a group of formula -Rn-(A) Z- in which Ru and A are as defined in claim 1, and z is equal to 2, 3 or 4.
10. A preparation method according to any one of the preceding claims, wherein the spacer is a direct bond or a formula group: preferably a direct link or a formula group:
11. A method of preparation according to any one of the preceding claims, wherein M is an active ingredient selected from: methotrexate, an immunomodulator, duocarmycin, combretastatin, calicheamicin, monomethylauristatin E (MMAE), monomethylauristatin F (MMAF), maytansine, DM1, DM4, SN38, amanitin and its analogues, pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, pyrrolopyridodiazepine, a pyrrolopyridodiazepine dimer, a histone deacetylase inhibitor, a tyrosine kinase inhibitor, ricin; preferably M is amanitin, a pyrrolobenzodiazepine dimer, MMAF or MMAE.
12. Antibody-drug conjugate mixture comprising predominantly either a structural conjugate (A), or a structural conjugate (B), or a structural conjugate (C), which is capable of being obtained by the process according to any one of the preceding claims, it being understood that when the mixture predominantly contains a structural conjugate (A), the two molecules of interest M attached to the antibody are different from each other.
13. Composition comprising a mixture of antibody-drug conjugates according to claim 12.
